Business
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights
– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers – – TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers – – Aaron Weitzman, M.D., F.A.C.P., appointed Chief Medical Officer – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2022, and provided business highlights. “We have made significant progress advancing our pipeline of synthetic lethal therapies, including the recent expansion of clinical trial sites for TNG908, our lead PRMT5 program, to include France, and the declaration of TNG348 as a development candidate for our USP1 program,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “In addition, we are very pleased to announce the appointment of Ron Weitzman, M.D. as our Chief Medical Officer. Dr. Weitzman has extensive experience in oncology clinical development, including both early and full development in solid tumors and hematologic malignancies, bringing expertise and leadership as we continue to progress our pipeline.” Recent Business Highlights Pipeline Update TNG908, a novel synthetic lethal PRMT5 inhibitor Enrollment is ongoing in the dose escalation phase of the TNG908 phase 1/2 trial.A CTA for TNG908 was approved by the ANSM in France during the fourth quarter of 2022.TNG908 is a synthetic lethal inhibitor of PRMT5 (protein arginine methyl transferase 5) that works selectively in cancer cells with MTAP (methylthioadenosine phosphorylase) deletion.MTAP deletions occur in approximately 10%-15% of all human cancers, including non-small cell lung cancer, mesothelioma, cholangiocarcinoma and glioblastoma. TNG260, a first-in-class CoREST complex inhibitor The Company disclosed the target of TNG260 as the CoREST complex. The CoREST complex (Co-repressor of Repressor Element-1 Silencing Transcription) plays a major role in regulating the expression of immunomodulatory proteins.Inhibition of the Co...